Yemaachi and Institut Pasteur Tunis Forge Oncogenetics Partnership to Sequence and Characterise Inflammatory Breast Cancer in Patients of African Descent
Partnership is emblematic of a global effort to characterise cancer development and progression in individuals of African descent, who have traditionally been excluded from genomic oncology studies and clinical trials 22nd October 2024, Tunis, Tunisia — Precision oncology company Yemaachi Biotech and Institut Pasteur Tunis today announced a research partnership investigating genomics in inflammatory breast […]
Oxford Nanopore announces participation in the PROGRESS study, with Yemaachi Biotech
A consortium of Yemaachi Biotech, Pediatric Oncology Units at Korle Bu Teaching Hospital, Komfo Anokye Teaching Hospital and Greater Accra Regional Hospital, and Newcastle University, have come together with Oxford Nanopore to support improved outcomes for childhood leukaemias in Ghana.
Team SAMBAI, including Yemaachi Biotech, named as recipient of prestigious Cancer Grand Challenges award
Team SAMBAI, led by Melissa B. Davis, PhD, of Morehouse School of Medicine, and comprised of collaborators from 14 institutions globally will receive $25M from Cancer Grand Challenges over five years to take on the challenge of cancer inequities